Inhibition of group IVA cytosolic phospholipase A2 by novel 2-oxoamides in vitro, in cells, and in vivo
The Group IVA cytosolic phospholipase A2 (GIVA PLA2) is a particularly attractive target for drug development because it is the rate-limiting provider of proinflammatory mediators. We previously reported the discovery of novel 2-oxoa
Kokotos, George,Six, David A.,Loukas, Vassilios,Smith, Timothy,Constantinou-Kokotou, Violetta,Hadjipavlou-Litina, Dimitra,Kotsovolou, Stavroula,Chiou, Antonia,Beltzner, Christopher C.,Dennis, Edward A.
p. 3615 - 3628
(2007/10/03)
Novel 2-oxoamide inhibitors of human group IVA phospholipase A2
A novel class of potent human cytosolic phospholipase A2 (GIVA PLA2) inhibitors was developed. These inhibitors were designed to contain the 2-oxoamide functionality and a free carboxyl group. Among the compounds tested, a longchain
Kokotos, George,Kotsovolou, Stavroula,Six, David A.,Constantinou-Kokotou, Violetta,Beltzner, Christopher C.,Dennis, Edward A.
p. 2891 - 2893
(2007/10/03)
More Articles about upstream products of 600143-16-6